CLOSEOUT LETTER
TEI Biosciences
- Recipient:
- TEI Biosciences
United States
- Issuing Office:
United States
| |
10903 New Hampshire Avenue Silver Spring, MD 20993 |
August 31, 2017
Robert Beuhler, Ph.D.
Vice President, Manufacturing and Quality
TEI Biosciences, Inc.
7 Elkins Street
Boston, MA 02127
Dear Dr. Beuhler:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter, CMS #459703, dated May 29, 2015. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CAPT Raquel Peat, PhD, MPH, USPHS
Director
Division of Premarket and Labeling Compliance
Office of Compliance
Center for Devices and Radiological Health